The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Busulfan plus cyclophosphamide versus busulfan plus fludarabine as a preparative regimen for allogeneic haemopoietic stem-cell transplantation in patients with acute myeloid leukaemia: an open-label, multicentre, randomised, phase 3 trial
Open accessAbstract
BACKGROUND The standard busulfan-cyclophosphamide myeloablative conditioning regimen is associated with substantial non-relapse mortality in patients older than 40 years with acute myeloid leukaemia who are undergoing allogeneic stem-cell transplantation. Because the combination of busulfan plus fludarabine has been proposed to reduce non-relapse mortality, we aimed to compare this treatment with busulfan plus cyclophosphamide as a preparative regimen in these patients. METHODS We did an open-label, multicentre, randomised, phase 3 trial for patients with acute myeloid leukaemia at 25 hospital transplant centres in Italy and one in Israel. Eligible patients were aged 40-65 years, had an Eastern Cooperative Oncology Group performance status less than 3, and were in complete remission. Patients were randomly assigned 1:1 to receive intravenous busulfan plus cyclophosphamide or busulfan plus fludarabine. Treatment allocations were not masked to investigators or patients. Randomisation was done centrally via a dedicated web-based system using remote data entry, with patients stratified by donor type and complete remission status. Patients allocated to busulfan plus cyclophosphamide received intravenous busulfan 0·8 mg/kg four times per day during 2 h infusions for four consecutive days (16 doses from days -9 through -6; total dose 12·8 mg/kg) and cyclophosphamide at 60 mg/kg per day for two consecutive days (on days -4 and -3; total dose 120 mg/kg). Patients allocated to busulfan plus fludarabine received the same dose of intravenous busulfan (from days -6 through -3) and fludarabine at 40 mg/m(2) per day for four consecutive days (from days -6 through -3; total dose 160 mg/m(2)). The primary endpoint was 1-year non-relapse mortality, which was assessed on an intention-to-treat basis; safety outcomes were assessed in the per-protocol population. This trial has been completed and is registered with ClinicalTrials.gov, number NCT01191957. FINDINGS Between Jan 3, 2008, and Dec 20, 2012, we enrolled and randomly assigned 252 patients to receive busulfan plus cyclophosphamide (n=125) or busulfan plus fludarabine (n=127). Median follow-up was 27·5 months (IQR 9·8-44·3). 1-year non-relapse mortality was 17·2% (95% CI 11·6-25·4) in the busulfan plus cyclophosphamide group and 7·9% (4·3-14·3) in the busulfan plus fludarabine group (Gray's test p=0·026). The most frequently reported grade 3 or higher adverse events were gastrointestinal events (28 [23%] of 121 patients in the busulfan plus cyclophosphamide group and 26 [21%] of 124 patients in the busulfan plus fludarabine group) and infections (21 [17%] patients in the busulfan plus cyclophosphamide group and 13 [10%] patients in the busulfan plus fludarabine group had at least one such event). INTERPRETATION In older patients with acute myeloid leukaemia, the myeloablative busulfan plus fludarabine conditioning regimen is associated with lower transplant-related mortality than busulfan plus cyclophosphamide, but retains potent antileukaemic activity. Accordingly, this regimen should be regarded as standard of care during the planning of allogeneic transplants for such patients. FUNDING Agenzia Italiana del Farmaco.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A Proportional Hazards Model for the Subdistribution of a Competing Risk
Fine, J. P., & Gray, R. J. (1999) · Journal of the American Statistical Association · doi:10.1080/01621459.1999.10474144 · Cited by 14,290
Cited by
Döhner, H., Estey, E., Grimwade, D., Amadori, S., Appelbaum, F. R., Büchner, T., Dombret, H., Ebert, B. L., Fenaux, P., Larson, R. A., et al. (2017) · Blood · doi:10.1182/blood-2016-08-733196 · Cited by 5,775
Hoelzer, D., Bassan, R., Dombret, H., Fielding, A., Ribera, J. M., & Buske, C. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw025 · Cited by 463
de Witte, T., Bowen, D., Robin, M., Malcovati, L., Niederwieser, D., Yakoub-Agha, I., Mufti, G. J., Fenaux, P., Sanz, G., Martino, R., et al. (2017) · Blood · doi:10.1182/blood-2016-06-724500 · Cited by 379
Self-citationHeuser, M., Ofran, Y., Boissel, N., Brunet Mauri, S., Craddock, C., Janssen, J., Wierzbowska, A., & Buske, C. (2020) · Annals of Oncology · doi:10.1016/j.annonc.2020.02.018 · Cited by 284
Harris, A. C., Boelens, J. J., Ahn, K. W., Fei, M., Abraham, A., Artz, A., Dvorak, C., Frangoul, H., Freytes, C., Gale, R. P., et al. (2018) · Blood Advances · doi:10.1182/bloodadvances.2018016956 · Cited by 33
Metadata
- Authors
- Rambaldi, A., Grassi, A., Masciulli, A., Boschini, C., Micò, M. C., Busca, A., Bruno, B., Cavattoni, I., Santarone, S., Raimondi, R., Montanari, M., Milone, G., Chiusolo, P., Pastore, D., Guidi, S., Patriarca, F., Risitano, A. M., Saporiti, G., Pini, M., Terruzzi, E., Arcese, W., Marotta, G., Carella, A. M., Nagler, A., Russo, D., Corradini, P., Alessandrino, E. P., Torelli, G. F., Scimè, R., Mordini, N., Oldani, E., Marfisi, R. M., Bacigalupo, A., & Bosi, A.
- Venue
- The Lancet Oncology
- Publisher
- Elsevier BV
- Published
- 2015-11
- Volume
- 16
- Issue
- 15
- Pages
- 1525-1536
- ISSN
- 1470-2045 (ISSN-L)
- OpenAlex
- W2148070164
- Cited by
- 179
- References
- 1
- FWCI
- 14.02
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Busulfan plus cyclophosphamide versus busulfan plus fludarabine as a preparative regimen for allogeneic haemopoietic stem-cell transplantation in patients with acute myeloid leukaemia: an open-label, multicentre, randomised, phase 3 trial. https://app.cochat.ai/papers/10.1016/s1470-2045(15)00200-4
- The paper
- Rambaldi, A., Grassi, A., Masciulli, A., Boschini, C., Micò, M. C., Busca, A., Bruno, B., Cavattoni, I., Santarone, S., Raimondi, R., Montanari, M., Milone, G., Chiusolo, P., Pastore, D., Guidi, S., Patriarca, F., Risitano, A. M., Saporiti, G., Pini, M., . . . Bosi, A. (2015). Busulfan plus cyclophosphamide versus busulfan plus fludarabine as a preparative regimen for allogeneic haemopoietic stem-cell transplantation in patients with acute myeloid leukaemia: an open-label, multicentre, randomised, phase 3 trial. The Lancet Oncology. https://doi.org/10.1016/s1470-2045(15)00200-4
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.